Jiangsu Hengrui Pharmaceuticals plans to list in Hong Kong! The hundred billion yuan pharmaceutical company ranks first among heavyweight in fund stocks in the A-share pharmaceutical sector.

On December 9, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that, after the approval of the board of directors, in order to further assist the company's international business development, the company plans to issue shares (listed in hong kong) overseas and list on the main board of the Hong Kong Stock Exchange.

brokerage chinaDec 10 07:53

0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.

① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.

cls.cnDec 9 18:34

The chapter comes to a close! The final version of the NDAA in both the House and Senate did not include the biological security bill. Will it make a comeback next year?

1. The final negotiation text of NDAA did not include the "Biosecurity Act", and the attempt to "ride on the coattails" failed again; 2. This year, the session of the US Congress will come to an end, experts believe that the legislation of the "Biosecurity Act" this year may come to a conclusion, but it may "come back with a vengeance" next year.

cls.cnDec 9 07:33

beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research

① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.

cls.cnNov 30 22:42

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement

① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.

cls.cnNov 27 21:14